Compare Becton Dickinson and Co (BDX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.65. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BDX | VCIT | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Fixed Income |
52-Week High | $185.39 | $84.82 |
52-Week Low | $135.49 | $81.45 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $81.45, down 0.44% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The fund maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective option for intermediate-duration corporate bond exposure. Recent dividend payments of $0.33-$0.34 per share demonstrate consistent income distribution to investors.
The outlook remains balanced with VCIT offering attractive yield characteristics amid moderate duration risk. Key considerations include interest rate sensitivity and corporate credit quality, with the fund providing diversification across 2,000+ investment-grade bonds. Market sentiment appears cautiously optimistic given the fund's low-cost structure and steady income profile in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
